Fri, Feb 27, 2015, 6:54 AM EST - U.S. Markets open in 2 hrs 36 mins


% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

  • dooper55 dooper55 Dec 4, 2012 7:48 AM Flag

    Needham upgraded Omeros based on valuation.

    Price target is $10.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • From StreetInsider .....

      The firm [Needham] comments, "Omeros is expected to announce results of a Phase 3 trial of OMS-103HP in meniscectomy surgery in the near future, presumably in Dec 2012. Although Omeros previously announced positive results from a Phase 2 trial in this indication, we have been concerned by Phase 3 trial failures with OMS103HP in ACL surgery in early 2011. Our essentially neutral sentiment towards the outcome of the Phase 3 OMS103HP trial is unchanged. However, we are adopting a more favorable overall view towards the stock given the announcement last month of positive results from a second Phase 3 trial of OMS302 in eye surgery and the recent drop in share price, leading to the current relatively low ~$175M EV. We do not believe the commercial opportunity for OMS302 in eye surgery is particularly large, but it may present a floor in case of a negative OMS103HP outcome. Consequently, we are upgrading to BUY. Our $10 price target is based on 25x our 2017 EPS estimate,
      discounted 15%."

20.93+0.29(+1.41%)Feb 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Emulex Corporation
NYSEThu, Feb 26, 2015 4:04 PM EST
Akorn, Inc.
NASDAQThu, Feb 26, 2015 4:00 PM EST